 Manja Zec
Concepts (209)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fatty Acid Desaturases | 3 | 2021 | 29 | 2.070 |
Why?
| | Fatty Acids | 10 | 2021 | 381 | 2.020 |
Why?
| | Phospholipids | 6 | 2021 | 197 | 1.290 |
Why?
| | Zinc | 5 | 2019 | 260 | 1.170 |
Why?
| | Polyphenols | 4 | 2021 | 16 | 1.070 |
Why?
| | Juglans | 5 | 2023 | 7 | 0.980 |
Why?
| | Semicarbazones | 3 | 2014 | 3 | 0.970 |
Why?
| | Coordination Complexes | 2 | 2014 | 11 | 0.860 |
Why?
| | Selenium Compounds | 2 | 2014 | 21 | 0.860 |
Why?
| | Overweight | 4 | 2023 | 472 | 0.840 |
Why?
| | Photinia | 5 | 2021 | 5 | 0.790 |
Why?
| | Vitamin D Deficiency | 2 | 2019 | 158 | 0.720 |
Why?
| | Arachidonic Acid | 1 | 2020 | 116 | 0.690 |
Why?
| | Recommended Dietary Allowances | 1 | 2019 | 18 | 0.670 |
Why?
| | Vitamin D | 2 | 2019 | 341 | 0.660 |
Why?
| | Plasma | 1 | 2021 | 211 | 0.640 |
Why?
| | Dyslipidemias | 1 | 2019 | 154 | 0.600 |
Why?
| | Metabolic Syndrome | 4 | 2023 | 321 | 0.580 |
Why?
| | Erythrocytes | 2 | 2019 | 591 | 0.560 |
Why?
| | Antineoplastic Agents | 4 | 2016 | 1879 | 0.520 |
Why?
| | Nickel | 2 | 2014 | 50 | 0.510 |
Why?
| | Cardiovascular Diseases | 6 | 2023 | 1727 | 0.490 |
Why?
| | Diet | 7 | 2023 | 1080 | 0.480 |
Why?
| | Biomarkers | 4 | 2019 | 3408 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1880 | 0.420 |
Why?
| | Fructose | 5 | 2023 | 100 | 0.370 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 523 | 0.360 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2022 | 122 | 0.340 |
Why?
| | Cross-Sectional Studies | 6 | 2020 | 4410 | 0.310 |
Why?
| | Linoleic Acid | 2 | 2019 | 37 | 0.300 |
Why?
| | Eating | 2 | 2021 | 344 | 0.300 |
Why?
| | Cadmium | 3 | 2014 | 58 | 0.300 |
Why?
| | Nuts | 3 | 2022 | 12 | 0.280 |
Why?
| | Dietary Fats | 2 | 2019 | 287 | 0.270 |
Why?
| | Blood Pressure | 3 | 2023 | 1538 | 0.260 |
Why?
| | Genotype | 2 | 2021 | 1760 | 0.250 |
Why?
| | Serbia | 3 | 2019 | 5 | 0.250 |
Why?
| | Diet, Mediterranean | 2 | 2022 | 20 | 0.240 |
Why?
| | Obesity | 4 | 2023 | 2508 | 0.240 |
Why?
| | Dietary Supplements | 2 | 2021 | 460 | 0.230 |
Why?
| | Hypertension | 2 | 2023 | 1056 | 0.230 |
Why?
| | Middle Aged | 13 | 2023 | 26738 | 0.230 |
Why?
| | Fruit and Vegetable Juices | 3 | 2020 | 11 | 0.230 |
Why?
| | Adult | 11 | 2021 | 30553 | 0.220 |
Why?
| | Plant Extracts | 3 | 2020 | 154 | 0.220 |
Why?
| | Feeding Behavior | 2 | 2019 | 574 | 0.220 |
Why?
| | Dietary Fats, Unsaturated | 2 | 2020 | 21 | 0.220 |
Why?
| | Obesity, Metabolically Benign | 1 | 2023 | 4 | 0.210 |
Why?
| | HeLa Cells | 3 | 2014 | 562 | 0.210 |
Why?
| | Nutritional Status | 3 | 2019 | 287 | 0.210 |
Why?
| | Female | 16 | 2021 | 59520 | 0.200 |
Why?
| | Group II Phospholipases A2 | 1 | 2021 | 19 | 0.190 |
Why?
| | Life Style | 2 | 2023 | 430 | 0.190 |
Why?
| | Glucose Transporter Type 2 | 1 | 2021 | 10 | 0.190 |
Why?
| | Glucose Transporter Type 3 | 1 | 2021 | 11 | 0.190 |
Why?
| | Energy Intake | 3 | 2020 | 427 | 0.190 |
Why?
| | Sirtuin 1 | 1 | 2021 | 29 | 0.180 |
Why?
| | Humans | 25 | 2023 | 114699 | 0.180 |
Why?
| | Gallic Acid | 1 | 2021 | 13 | 0.180 |
Why?
| | Catalase | 1 | 2021 | 118 | 0.180 |
Why?
| | Glucose Transporter Type 1 | 1 | 2021 | 42 | 0.180 |
Why?
| | Eicosapentaenoic Acid | 1 | 2021 | 28 | 0.180 |
Why?
| | KATP Channels | 1 | 2020 | 16 | 0.180 |
Why?
| | Cell Line, Tumor | 5 | 2014 | 2710 | 0.180 |
Why?
| | Male | 15 | 2023 | 55606 | 0.180 |
Why?
| | Hypothalamus | 1 | 2021 | 147 | 0.170 |
Why?
| | gamma-Linolenic Acid | 1 | 2019 | 2 | 0.170 |
Why?
| | Cholesterol | 2 | 2019 | 367 | 0.170 |
Why?
| | Libya | 1 | 2019 | 1 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2020 | 84 | 0.170 |
Why?
| | Transients and Migrants | 1 | 2019 | 22 | 0.170 |
Why?
| | Calcium Channels | 1 | 2020 | 145 | 0.160 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2019 | 45 | 0.160 |
Why?
| | Neoplasms | 3 | 2022 | 2097 | 0.160 |
Why?
| | Magnesium | 1 | 2019 | 145 | 0.160 |
Why?
| | Sunlight | 1 | 2019 | 57 | 0.160 |
Why?
| | Copper | 1 | 2019 | 100 | 0.160 |
Why?
| | Body Weight | 2 | 2021 | 869 | 0.160 |
Why?
| | Metabolic Diseases | 1 | 2019 | 98 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 398 | 0.150 |
Why?
| | Iron | 1 | 2019 | 233 | 0.150 |
Why?
| | Alleles | 1 | 2021 | 789 | 0.150 |
Why?
| | Leukocytes, Mononuclear | 1 | 2020 | 493 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 284 | 0.140 |
Why?
| | Heart | 1 | 2021 | 612 | 0.140 |
Why?
| | Pyridines | 2 | 2011 | 425 | 0.140 |
Why?
| | Rats | 5 | 2023 | 4958 | 0.140 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2016 | 6 | 0.140 |
Why?
| | Hippocampus | 1 | 2021 | 693 | 0.140 |
Why?
| | Membrane Lipids | 2 | 2014 | 87 | 0.140 |
Why?
| | Placebos | 1 | 2017 | 197 | 0.130 |
Why?
| | Cytochromes c | 2 | 2014 | 63 | 0.130 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 33 | 0.130 |
Why?
| | Cause of Death | 1 | 2018 | 361 | 0.130 |
Why?
| | Apoptosis | 4 | 2012 | 2363 | 0.130 |
Why?
| | Cell Cycle | 3 | 2014 | 542 | 0.130 |
Why?
| | Rats, Wistar | 3 | 2021 | 368 | 0.130 |
Why?
| | Caspase 3 | 2 | 2014 | 235 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2016 | 149 | 0.120 |
Why?
| | Mannans | 1 | 2014 | 4 | 0.120 |
Why?
| | Adiposity | 1 | 2019 | 458 | 0.120 |
Why?
| | Taste | 1 | 2017 | 208 | 0.120 |
Why?
| | Obesity, Abdominal | 1 | 2014 | 37 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.120 |
Why?
| | Beverages | 1 | 2014 | 60 | 0.120 |
Why?
| | Cations, Divalent | 1 | 2014 | 51 | 0.110 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 74 | 0.110 |
Why?
| | Incidence | 1 | 2019 | 2313 | 0.110 |
Why?
| | Organ Specificity | 1 | 2014 | 268 | 0.110 |
Why?
| | Necrosis | 1 | 2014 | 211 | 0.110 |
Why?
| | Precision Medicine | 1 | 2016 | 337 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2020 | 2553 | 0.100 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2012 | 57 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2012 | 119 | 0.100 |
Why?
| | Breast | 1 | 2012 | 139 | 0.100 |
Why?
| | Intercalating Agents | 1 | 2011 | 5 | 0.100 |
Why?
| | Malonates | 1 | 2011 | 7 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 531 | 0.090 |
Why?
| | Selenium | 1 | 2011 | 31 | 0.090 |
Why?
| | Cobalt | 1 | 2011 | 46 | 0.090 |
Why?
| | Azides | 1 | 2011 | 46 | 0.090 |
Why?
| | Antioxidants | 1 | 2014 | 530 | 0.090 |
Why?
| | Angiogenesis Inhibitors | 1 | 2012 | 214 | 0.090 |
Why?
| | Heart Failure | 1 | 2023 | 1945 | 0.090 |
Why?
| | Animals | 8 | 2023 | 31708 | 0.090 |
Why?
| | Breast Neoplasms | 2 | 2012 | 1862 | 0.090 |
Why?
| | Risk Factors | 5 | 2023 | 8632 | 0.090 |
Why?
| | Cell Survival | 1 | 2014 | 1021 | 0.090 |
Why?
| | Metals | 1 | 2011 | 106 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1040 | 0.090 |
Why?
| | Organoselenium Compounds | 1 | 2010 | 11 | 0.090 |
Why?
| | Aged | 4 | 2021 | 19074 | 0.080 |
Why?
| | South Africa | 2 | 2019 | 161 | 0.080 |
Why?
| | Gene Expression | 1 | 2014 | 1421 | 0.080 |
Why?
| | Cell Movement | 1 | 2012 | 869 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4624 | 0.080 |
Why?
| | Cell Line | 1 | 2012 | 2637 | 0.070 |
Why?
| | Phytotherapy | 2 | 2019 | 66 | 0.070 |
Why?
| | Mitochondria | 1 | 2011 | 747 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2011 | 951 | 0.060 |
Why?
| | Cations | 1 | 2023 | 78 | 0.050 |
Why?
| | Body Mass Index | 2 | 2023 | 1959 | 0.050 |
Why?
| | PPAR alpha | 1 | 2022 | 52 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2023 | 430 | 0.050 |
Why?
| | Sodium-Calcium Exchanger | 1 | 2020 | 13 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2021 | 620 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 124 | 0.040 |
Why?
| | Mice | 2 | 2012 | 14871 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2019 | 30 | 0.040 |
Why?
| | Cell Death | 1 | 2020 | 323 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2011 | 473 | 0.040 |
Why?
| | Waist Circumference | 1 | 2019 | 122 | 0.040 |
Why?
| | Fruit | 1 | 2019 | 127 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2021 | 447 | 0.040 |
Why?
| | Prospective Studies | 2 | 2019 | 6220 | 0.040 |
Why?
| | Survival Rate | 1 | 2021 | 1644 | 0.040 |
Why?
| | Centralized Hospital Services | 1 | 2016 | 6 | 0.030 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 86 | 0.030 |
Why?
| | Platelet Activation | 1 | 2017 | 68 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2018 | 224 | 0.030 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2016 | 24 | 0.030 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2016 | 34 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2017 | 94 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 945 | 0.030 |
Why?
| | Alanine Transaminase | 1 | 2017 | 142 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 897 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1569 | 0.030 |
Why?
| | Homozygote | 1 | 2016 | 187 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 1660 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 989 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 251 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 313 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 228 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 372 | 0.030 |
Why?
| | Creatinine | 1 | 2017 | 425 | 0.030 |
Why?
| | Nitric Oxide | 1 | 2020 | 823 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 2797 | 0.030 |
Why?
| | Gene Frequency | 1 | 2016 | 477 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1075 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 725 | 0.030 |
Why?
| | Triglycerides | 1 | 2017 | 467 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2540 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 610 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2016 | 554 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2020 | 2187 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 3003 | 0.030 |
Why?
| | Pilot Projects | 1 | 2017 | 1373 | 0.030 |
Why?
| | Artemia | 1 | 2011 | 8 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2011 | 135 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2011 | 81 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 157 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2011 | 248 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6347 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 2968 | 0.020 |
Why?
| | Registries | 1 | 2018 | 1768 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 4895 | 0.020 |
Why?
| | Molecular Structure | 1 | 2010 | 434 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 402 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1147 | 0.020 |
Why?
| | Kinetics | 1 | 2011 | 1551 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 4515 | 0.020 |
Why?
| | Time Factors | 1 | 2016 | 6116 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3346 | 0.020 |
Why?
| | DNA | 1 | 2011 | 1352 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 17853 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 9088 | 0.010 |
Why?
| | Child | 1 | 2021 | 18420 | 0.010 |
Why?
| | United States | 1 | 2018 | 12186 | 0.010 |
Why?
|
|
Zec's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|